MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- STRIDES PHARMA SCIENCE - MYLAN (US)
STRIDES PHARMA SCIENCE vs MYLAN (US) - Comparison Results
STRIDES PHARMA SCIENCE Change
Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 STRIDES PHARMA SCIENCE  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| STRIDES PHARMA SCIENCE Mar-18 |
MYLAN Dec-18 |
STRIDES PHARMA SCIENCE/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,147 | 3,561 | - | |
| Low | Rs | 642 | 1,960 | - | |
| Sales per share (Unadj.) | Rs | 317.2 | 1,638.8 | - | |
| Earnings per share (Unadj.) | Rs | 7.8 | 44.5 | - | |
| Cash flow per share (Unadj.) | Rs | 25.1 | 351.3 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 274.3 | 1,772.8 | - | |
| Shares outstanding (eoy) | m | 89.50 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.8 | 1.7 | 167.4% | |
| Avg P/E ratio | x | 114.0 | 62.0 | 183.8% | |
| P/CF ratio (eoy) | x | 35.7 | 7.9 | 454.3% | |
| Price / Book Value ratio | x | 3.3 | 1.6 | 209.4% | |
| Dividend payout | % | 25.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 80,058 | 1,420,461 | 5.6% | |
| No. of employees | `000 | 2.5 | 35.0 | 7.2% | |
| Total wages/salary | Rs m | 4,341 | 0 | - | |
| Avg. sales/employee | Rs Th | 11,325.8 | 24,089.9 | 47.0% | |
| Avg. wages/employee | Rs Th | 1,731.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 280.1 | 654.1 | 42.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 28,394 | 843,147 | 3.4% | |
| Other income | Rs m | 941 | 0 | - | |
| Total revenues | Rs m | 29,334 | 843,147 | 3.5% | |
| Gross profit | Rs m | 3,965 | 218,175 | 1.8% | |
| Depreciation | Rs m | 1,540 | 157,870 | 1.0% | |
| Interest | Rs m | 1,962 | 40,552 | 4.8% | |
| Profit before tax | Rs m | 1,403 | 19,752 | 7.1% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -168 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -436 | 0 | - | |
| Tax | Rs m | 97 | -3,142 | -3.1% | |
| Profit after tax | Rs m | 702 | 22,895 | 3.1% | |
| Gross profit margin | % | 14.0 | 25.9 | 54.0% | |
| Effective tax rate | % | 6.9 | -15.9 | -43.6% | |
| Net profit margin | % | 2.5 | 2.7 | 91.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 24,836 | 470,812 | 5.3% | |
| Current liabilities | Rs m | 18,993 | 343,274 | 5.5% | |
| Net working cap to sales | % | 20.6 | 15.1 | 136.0% | |
| Current ratio | x | 1.3 | 1.4 | 95.3% | |
| Inventory Days | Days | 71 | 84 | 84.9% | |
| Debtors Days | Days | 113 | 93 | 121.5% | |
| Net fixed assets | Rs m | 34,289 | 163,557 | 21.0% | |
| Share capital | Rs m | 895 | 449 | 199.4% | |
| Net worth | Rs m | 24,546 | 912,131 | 2.7% | |
| Long term debt | Rs m | 15,513 | 984,482 | 1.6% | |
| Total assets | Rs m | 65,437 | 2,446,689 | 2.7% | |
| Interest coverage | x | 1.7 | 1.5 | 115.3% | |
| Debt to equity ratio | x | 0.6 | 1.1 | 58.6% | |
| Sales to assets ratio | x | 0.4 | 0.3 | 125.9% | |
| Return on assets | % | 4.1 | 2.6 | 157.0% | |
| Return on equity | % | 2.9 | 2.5 | 114.0% | |
| Return on capital | % | 6.9 | 3.2 | 216.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,871 | 175,206 | 1.1% | |
| From Investments | Rs m | 5,826 | -90,562 | -6.4% | |
| From Financial Activity | Rs m | -10,157 | -81,621 | 12.4% | |
| Net Cashflow | Rs m | -2,615 | 1,452 | -180.1% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.82 Rs / USD
Compare STRIDES PHARMA SCIENCE With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare STRIDES PHARMA SCIENCE With: UNICHEM LAB DR. REDDYS LAB LUPIN SUVEN LIFE SCIENCES DR. DATSONS LABS
Today's Market
Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views On News
STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)
Feb 5, 2021 | Updated on Feb 5, 2021For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)
Aug 20, 2020 | Updated on Aug 20, 2020For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
An India Revival Stock I'm Bullish On... (Profit Hunter)
Apr 9, 2021This could take India to the position of 3rd largest economy.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
More
